Related Experiment Video
Updated: Mar 11, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Chronic myeloid leukemia: sequencing of TKI therapies
Jorge Cortes1, Hagop Kantarjian1
1Department of Leukemia, MD Anderson Cancer Center, Houston, TX.
Abstract:
Multiple tyrosine kinase inhibitors (TKIs) are available for managing patients with chronic myeloid leukemia. Although most patients have a favorable outcome with their initial therapy, whether imatinib or a second-generation TKI was used, some will require subsequent use of one or more different TKIs. Such sequencing might be indicated in a reactive way (ie, for patients who have experienced resistance or intolerance to their initial therapy) or in a proactive way (ie, for patients with a somewhat favorable outcome who have not reached an "optimal" outcome). Sequencing of TKIs has become standard practice, and the proper use of sequenced TKIs is likely to optimize outcomes and resource utilization.
Insights
Patients with chronic myeloid leukemia (CML) may need sequential tyrosine kinase inhibitors (TKIs) if initial treatment fails or is suboptimal. Strategic sequencing of TKIs can improve patient outcomes and resource use.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic myeloid leukemia (CML) is manageable with tyrosine kinase inhibitors (TKIs).
- Initial TKI therapy is effective for most CML patients.
- Some patients require switching or adding TKIs due to resistance or intolerance.
Purpose of the Study:
- To discuss the role of sequencing tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) management.
- To highlight indications for TKI sequencing, including reactive and proactive strategies.
- To emphasize the importance of proper TKI sequencing for optimizing patient outcomes and resource allocation.
Main Methods:
- Review of current clinical practices and literature on TKI sequencing in CML.
- Analysis of reactive (resistance/intolerance) and proactive (suboptimal response) TKI sequencing strategies.
- Discussion on optimizing TKI sequences for improved efficacy and cost-effectiveness.
Main Results:
- Sequential TKI therapy is a standard approach in CML management.
- Both reactive and proactive sequencing strategies are employed.
- Effective TKI sequencing can lead to better patient outcomes and efficient use of healthcare resources.
Conclusions:
- Sequencing of TKIs is a crucial component of modern CML treatment.
- Tailoring TKI sequences based on patient response and tolerance is essential.
- Optimized TKI sequencing holds promise for improving long-term CML management and resource utilization.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase